The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Giant Cell Arteritis Challenging to Diagnose, Manage

Giant Cell Arteritis Challenging to Diagnose, Manage

March 1, 2015 • By Sebastian Unizony, MD, and John H. Stone, MD, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Giant Cell Arteritis Challenging to Diagnose, Manage

Giant cell arteritis (GCA) is a relatively common rheumatologic disease with potentially devastating complications. It was first described in the early 1890s; however, more than a hundred years later, this large- and medium-sized vessel vasculitis continues to pose multiple challenges for rheumatologists and patients in terms of diagnosis and therapy, as well as the management and prevention of treatment complications.

You Might Also Like
  • Giant Cell Arteritis
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Explore This Issue
March 2015

GCA is the most common form of primary vasculitis among adults in Western countries, with a prevalence ranging from 24 to 280 cases per 100,000 individuals older than 50. The incidence of GCA increases progressively with age and peaks during the seventh decade of life. The disease has a particular predilection for elderly populations of northern European ancestry and is approximately twice as common in women than in men.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The main histopathologic feature of GCA comprises a chronic granulomatous inflammatory process that involves the aorta and its main branches, with a tendency to affect the extracranial carotid arteries and the ophthalmic circulation (see Figure 1). Its clinical manifestations consist of constitutional symptoms (e.g., asthenia, fever), headaches, jaw claudication, shoulder and hip girdle pain and stiffness (i.e., polymyalgia rheumatica) and elevated acute-phase reactants.2

The most feared consequence of GCA pertains to vision loss, occurring in 15–20% of cases. Blindness, which tends to occur before the disease is even suspected, usually occurs as the result of anterior ischemic optic neuropathy (AION) due to the occlusion of the long posterior ciliary arteries that perfuse the head of the optic nerve.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other possible complications include scalp and tongue necrosis, aortic aneurysm, aortic dissection, limb claudication from large-artery stenosis (particularly the subclavian and axillary arteries), stroke, mesenteric ischemia, myocardial infarction and venous thromboembolism.2

Classification Criteria

In 1990, the ACR classification criteria were established for the purpose of differentiating GCA from other vasculitides.3 The five components of the ACR classification criteria for GCA are shown in Table 1 (p. 22). Fulfillment of at least three of the five ACR criteria is associated with a 90% sensitivity and a 90% specificity for GCA when evaluating patients known to have one form of systemic vasculitis or another. The ACR classification criteria were not designed for use as diagnostic criteria, but rather for the purpose of ensuring greater uniformity of patient populations in studies of vasculitis.

Rendering the diagnosis of GCA is often considerably more challenging than referring to the features of the ACR classification criteria, however. The evaluation of cranial symptoms—common complaints in clinic populations—requires substantial experience and judgment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: Diagnosis, Giant Cell Arteritis, Research, rheumatology, Stone, Treatment, Unizony, VasculitisIssue: March 2015

You Might Also Like:
  • Giant Cell Arteritis
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.